Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC.
Fiche publication
Date publication
mai 2023
Journal
Frontiers in radiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
Tous les auteurs :
Bouhamama A, Leporq B, Faraz K, Foy JP, Boussageon M, Pérol M, Ortiz-Cuaran S, Ghiringhelli F, Saintigny P, Beuf O, Pilleul F
Lien Pubmed
Résumé
In this study, we aim to build radiomics and multiomics models based on transcriptomics and radiomics to predict the response from patients treated with the PD-L1 inhibitor.
Mots clés
NSCLC, PD-L1 inhibitors, immunotherapy, radiomics, transcriptomics
Référence
Front Radiol. 2023 05 3;3:1168448